Minocycline (7-dimethylamino-6-dimethyl-6-deoxytetracycline) is a second-generation tetracycline that can cross the blood -brain barrier and has anti-inflammatory and neuroprotective effects. The potential of minocycline as a drug for treating Huntington's disease has been studied; however, the molecular mechanism underlying the neuroprotective properties of minocycline remains elusive. In this study, we tested the hypothesis that a principal cellular target of minocycline is Apaf-1, a key protein in the formation of the apoptosome, a multiprotein complex involved in caspase activation. Minocycline binds to Apaf-1, as shown by nuclear magnetic resonance spectroscopy, and inhibits apoptosome activity in vitro and in ex vivo models. As a consequence, minocycline-treated cells as well as Apaf-1 knock-out cells are resistant to the development of mutant huntingtin-dependent protein aggregation.
INTRODUCTION
Apoptosis, or programmed cell death, is a key cellular mechanism that is involved in a broad range of physiological processes. Deregulated apoptosis is associated with several human pathologies, such as cancer, ischemic injuries and neurodegenerative disorders. To identify molecules that could ameliorate disease-associated apoptosis, drug discovery efforts initially targeted caspase activity (1, 2) . However, there are physiological compensatory mechanisms that are invoked when some caspases are inhibited (3, 4) . Furthermore, there have been difficulties in developing caspase-3 inhibitors for use as pharmacological agents and, despite intensive research, none has been approved by regulatory agencies (5) . For this reason, inhibition of cell death upstream of caspase activation could be valuable as a way to modulate apoptosis pathways.
The apoptosome holoenzyme is a multiprotein complex formed by cytochrome c (Cyt c)-activated apoptotic protease-activating factor (Apaf-1), dATP and procaspase-9 (pc9) (6, 7) . In this macromolecular complex, apoptosomeassociated caspase-9 is activated, which in turn activates effector caspases. Data suggest that inhibition of apoptosome assembly might represent an interesting target for apoptosis modulators (8 -11) .
Minocycline (7-dimethylamino-6-dimethyl-6-deoxytetracycline) is a second-generation tetracycline antibiotic that can cross the blood -brain barrier (12) and is also used for its anti-inflammatory and neuroprotective effects (13) (14) (15) (16) . This broad-spectrum antibiotic has a number of clinical properties that are useful for treating rheumatoid arthritis, sarcoidosis, autoimmune disorders, ischemia and neurodegenerative diseases (17, 18 ). Minocycline appears to have multi-faceted effects. Minocycline-mediated neuroprotection may stem from inhibition of caspase-1, caspase-3 and inducible nitric oxide synthase transcriptional upregulation and activation (10, 13, 19) . Inhibition of microglial activation (15) and the p38 mitogen-activated protein kinase pathway (20) may also be involved in minocycline-mediated neuroprotection. Several groups have reported that minocycline prevents Cyt c release from mitochondria, a key step in apoptosis. Pioneering work by Friedlander and colleagues showed that minocycline inhibits Cyt c release in rodent models of amyotrophic lateral sclerosis (10), Huntington's disease (HD) (9) and spinal cord injury (21) . The authors suggested that such minocyclinedependent Cyt c release inhibition was mediated by the * To whom correspondence should be addressed at: mitochondrial permeability transition pore (MPT) (9, 10, 21) . Along the same lines, Scarabelli et al. (22) showed that minocycline significantly increases the X-linked inhibitor of apoptosis protein to Smac/DIABLO ratio at both the mRNA and protein levels, preventing Cyt c and Smac/DIABLO release from mitochondria . It has been also reported that under stressful or pathological conditions, minocycline protects mitochondria by upregulating anti-apoptotic Bcl-2 and downregulating the pro-apoptotic Bax, Bak, Bid (23, 24) and Fas (25) proteins. Some researchers suggest that this protection is the result of decreased membrane damage and Cyt c release, which blocks downstream caspase activation (23) (24) (25) . In contrast, others suggest that the neuroprotective mechanism of minocycline in animal models and humans is not related to the inhibition of MPT (26, 27) . There are some apparent discrepancies in the reported cellular targets of minocycline that may be related to differences in experimental conditions. Despite all the data, the exact mechanism underlying the neuroprotective properties of minocycline remains elusive.
Minocycline neuroprotection has been studied extensively in HD models, although preliminary clinical studies have not been conclusive. HD is a neurodegenerative genetic disorder with autosomal dominant inheritance. The disease is caused by the expansion of a CAG trinucleotide repeat that codes for the amino acid glutamine (Gln or Q), in exon 1 of the gene for the huntingtin protein (Htt). The mutant protein (mt Htt), which has a longer polyQ sequence at the N-terminus (Nt) than the wild-type protein, accumulates and aggregates in neurons, leading to high levels of apoptosis and neuronal death (28) . There is solid evidence that mt Htt caspase-dependent proteolysis and release of the Nt polyQ-containing fragment correlate with pathogenesis (29) (30) (31) (32) (33) (34) . The role of polyQ aggregates and the molecular mechanism underlying the pathological development of HD are still unknown. Interestingly, a Drosophila model of HD shows that inactivation of the dark gene (Drosophila Apaf-1 related killer) suppresses the formation of polyQ aggregates and diminishes the associated pathogenesis (35) .
Here, we report experimental evidence that minocycline binds to and inhibits Apaf-1. Because minocycline-dependent Apaf-1 inhibition decreases mt Htt-induced toxicity in cells, we further investigated whether Apaf-1 has a non-apoptosis-related role in the pathology of protein-aggregation-dependent neurodegenerative diseases such as HD. Importantly, we showed that Apaf-1-deficient cells are less prone to developing aggregates than are wild-type cells, thereby supporting the involvement of Apaf-1 in a mammalian model of polyQ-related diseases.
RESULTS

Minocycline inhibits apoptosome activity in vitro
We initially tested whether minocycline can influence the activity of an in vitro reconstituted apoptosome (36) . Recombinant Apaf-1 (rApaf-1), recombinant pc9 and commercial Cyt c were combined in the presence of dATP to obtain a functional apoptosome. The apoptosome-mediated activation of pc9 was detected using the fluorogenic pc9 substrate, Ac-LEHD-afc (see Materials and Methods). In the presence of minocycline, apoptosome activity was inhibited and the IC 50 (compound concentration that provides 50% inhibition of the apoptosome activity) value was 54 mM (Fig. 1A) . We also tested whether minocycline inhibited pc9 directly, but no direct inhibition was observed in a forced dimerization-activated recombinant pc9 assay (37) (Supplementary Material, Fig. S1A ; see Materials and Methods).
In the cellular milieu, molecules that have activity in cell-free assays may interact with other molecules that mitigate their effects. To investigate minocycline activity in a cellular environment, its activity was assayed in a mammalian cellular extract. Specifically, cytosolic extracts of a human embryonic kidney cell line (HEK293) were depleted of Apaf-1 by ionic fractionation (38, 39) . This extract is a convenient experimental tool for analyzing induction of apoptosis under experimentally controlled conditions (40) . In fact, incubation of the depleted cell extract with rApaf-1 and dATP (41) restored the apoptotic pathway; this restoration was detected using a fluorogenic substrate for the effector, caspase-3 (Ac-DEVD-afc). Minocycline treatment inhibited Apaf-1-induced activation of caspase 3 ( Fig. 1B) , suggesting a direct effect of minocycline over Apaf-1 activity.
Minocycline interacts physically with Apaf-1
The interaction between minocycline and Apaf-1 was analyzed by nuclear magnetic resonance (NMR) spectroscopy. We applied two complementary ligand-based NMR techniques that analyze the effects of ligand binding on NMR signals: waterLOGSY (water-ligand observed by gradient spectroscopy) (42) and STD (saturation transfer difference) (43) . In these techniques, an excess of ligand is mixed with the target protein (here, minocycline and Apaf-1), and the exchange between the bound and free states of the ligand modulates the NMR signal of the free ligand. The STD experiment involves acquisition of two spectra, one with all the protons of the target protein saturated and the other without saturation. If the ligand is bound to the target protein, it will also be saturated in the first spectrum, and this saturation will be transferred via exchange to the free ligand. The difference between the two spectra represents signals that arise from the bound ligand: a non-binding ligand will produce the same spectrum with and without saturation, and therefore its signals will cancel each other out. The waterLOGSY experiment makes use of the water molecules bound at the targetligand interface to selectively transfer the magnetization from the complex to the free ligand. Then, the interaction between the ligand and its target protein is characterized by a positive signal in the 1D 1 H spectrum or by a reduction in the negative signal in the reference spectrum (i.e. the spectrum recorded in the absence of the target protein). Figure 2A shows the 1D 1 H spectrum of a mixture of rApaf-1 (1 mM) and minocycline (100 mM). Under these conditions, rApaf-1 is not observed in the NMR spectrum, and the only signals are those from minocycline and other chemicals in the buffer. In the waterLOGSY experiment (Fig. 2B) , some of the signals from the molecule were positive (b and f), whereas the signals from the minocycline N(Me)2 groups (c and i) were both positive and negative. The negative resonances observed in the spectrum were from other chemicals in the mixture buffer. A control waterLOGSY spectrum recorded in the absence of Apaf-1 showed negative signals for minocycline (not shown). The STD experiment (Fig. 2C) showed weak positive signals arising from several minocycline resonances, whereas the non-binding buffer components did not show signals in the spectrum. Taken together, these results show that minocycline binds to rApaf-1.
Although the relative intensity of the STD NMR signals can, in principle, provide information about the binding epitope (such as the most intense signal arising from the moiety in direct contact with the target), our results did not show any substantial difference in the minocycline signals. For example, the N(Me)2 groups showed similar intensities. Therefore, these initial data provided no To further analyze such observation, the in vitro reconstituted apoptosome assay was performed with rApaf1 1 -541 and minocycline; this combination did not inhibit caspase-9 activation (Supplementary Material, Fig. S1B ). It is tempting to speculate that if minocycline binds to the WD40 domains, then it should exert some competition with the natural WD40 domain-binder Cyt c. Then, although the binding of Cyt c to the WD40 domains is in the nanomolar range (46), we should expect a modest competition between minocycline and Cyt c. In fact, in the in vitro experimental setting, minocycline exerted a higher inhibitory activity at low concentrations of Cyt c than when Cyt c concentration is increased (Supplementary Material, Fig. S1C ).
Minocycline inhibits cell death and caspase activation in SV40-transformed wild-type mouse embryonic fibroblasts but not in Apaf-1 knockout mouse embryonic fibroblasts
The results from the NMR experiments and the reconstituted apoptosome assay suggested that minocycline binds to and inhibits Apaf-1. We next used a cell-based model to characterize Apaf-1 as a target of minocycline. After treatment with etoposide, both wild-type mouse embryonic fibroblasts (wtMEFs) and Apaf-1 knockout mouse embryonic fibroblasts (AkoMEFs) cells showed signs of cell death induction (Fig. 3A) ; this was caspase-3-dependent in wtMEFs but caspase-3-independent in AkoMEFs (Fig. 3B) . Interestingly, minocycline-mediated inhibition of etoposide-induced cell death and caspase-3 activity were only effective in wtMEFs (Fig. 3A and B) . Cell death and caspase-3 activity in AkoMEFs upon etoposide treatment were not rescued by minocycline ( Fig. 3A and B) . Thus, the protective effect of minocycline requires the presence of Apaf-1 in the cell. Confirmatory western blots are shown in Figure 3C . Specifically, when etoposide-challenged cells were treated with minocycline, caspase 9 and caspase 3 processing was reduced, whereas Bcl-xl levels were recovered to control, confirming the protective effect of minocycline treatment. Similarly, when cells were treated with TNFa, which activates the extrinsic receptor- 3548 Human Molecular Genetics, 2011, Vol. 20, No. 18 mediated apoptosis pathway, caspase-3 activity was observed both in wtMEFs and in AkoMEFs (Fig. 3D) . TNFa-induced death was not inhibited by minocycline (Fig. 3D) . Taken together, these results confirmed that minocycline inhibits intrinsic (mitochondrial-mediated) but not extrinsic-mediated apoptosis activation through an inhibitory effect on Apaf-1 activity. Furthermore, we evaluated several intrinsic apoptosis inducers, such as cisplatin and doxorubicin, with similar results (not shown). In order to generalize our observations to a wide range of cell lines, we tried to develop an shRNAdependent method to deplete Apaf-1; however, as has been reported by others, full depletion of Apaf-1 could not be achieved (47, 48) . Thus, we propose that the direct binding of minocycline to Apaf-1 inhibits apoptosome activity by interfering with apoptosome formation or with the binding of Cyt c to Apaf-1.
Cyt c release is not affected by minocycline in AkoMEFs
Friedlander and colleagues proposed that the activity of minocycline is related to inhibition of Cyt c release from mitochondria, although recent studies have suggested alternative explanations for the molecular mechanism of action of minocycline as a neuroprotectant (26, 27) . Notably, there were differences in the cellular models and experimental conditions used by the different research groups. It is possible that there are several mechanisms underlying the neuroprotective effect that are not mutually exclusive and that operate in parallel. Surprisingly, we observed inhibition of Cyt c release when etoposide-challenged wtMEFs were treated with minocycline (Fig. 4A ). This effect was not observed in AkoMEFs, although etoposide induced Cyt c release into the cytosol (Fig. 4B ). These observations indicate that minocycline requires Apaf-1 for its action and that Apaf-1 plays a role in regulating Cyt c dynamics, in agreement with previous research (47) .
Involvement of Apaf-1 in HD
A neuroprotective effect for minocycline has been described in experimental models of HD. HeLa cells transiently expressing an mt Htt exon 1 fragment with 74 polyQ repeats (Q74) fused to GFP (EGFP-HDQ74) were analyzed by fluorescence microscopy 72 h after transfection (49, 50) . Observations revealed a minocycline-dependent reduction of protein aggregates (Fig. 5A) , suggesting that minocycline can modify polyQ toxicity and aggregation in polyQ aggregation models. Because we found that minocycline binds to and inhibits Apaf-1, we next asked whether Apaf-1 has a role in HD-related protein aggregation events. For that purpose, we first showed that pan-caspase inhibitor (z-VAD) does not affect polyQ aggregation in our model and instead, Apaf-1 overexpression slightly enhances the formation of inclusions (Fig. 5B) . Next, AkoMEFs were transfected with EGFP-tagged huntingtin exon 1 with 23 polyQ repeats (EGFP-HDQ23-wt) or with EGFP-HDQ74 in order to analyze differences in protein aggregation. Figure 5C shows that AkoMEFs have less protein aggregates than the wtMEFs. In these conditions, treatment with minocycline does not reduce aggregation in Apaf-1 null cells (Fig. 5D) , confirming Apaf-1 as a target of minocycline. These results provide the first reported evidence of Apaf-1 involvement in HD in a mammalian cell model.
DISCUSSION
Minocycline is an attractive candidate for the treatment of neurodegenerative diseases because of its proven safety record in humans and its blood -brain barrier permeability. Although different mechanisms of action for minocycline have been proposed, including both caspase-independent and caspase-dependent pathways, the main cellular target of minocycline has remained elusive. This study shows that minocycline targets and exerts an inhibitory effect on Apaf-1, the key protein in the apoptosome, in in vitro, in cell-free and cellbased assays (Fig. 1) . This inhibition correlated with the ability of minocycline to protect cells against apoptosis triggers in wtMEFs but, interestingly, not in AkoMEFs (Figs 3  and 4) . Thus, Apaf-1 is required for minocycline-dependent inhibition of cell death. A noticeable effect of minocycline was its ability to also restore the in cell protein levels of the Bcl-2 anti-apoptotic protein Bcl-xL in cells challenged with the different apoptosis triggers evaluated (Fig. 3) . Furthermore, the formation of polyQ-dependent protein aggregates is drastically reduced in AkoMEFs but increased upon Apaf-1 overexpression (Fig. 5) , supporting a role for Apaf-1 in mammalian cellular models of polyQ-dependent toxic protein aggregation. Interestingly, such effects were not caspase-dependent as demonstrated when the experiments devoted to analyze the influence of Apaf-1 were performed in the presence of a pan-caspase inhibitor (Fig. 5B) . The role of Bcl-2 proteins and adaptor proteins like Apaf-1 in apoptosis have been well described (51) . However, recent evidence suggests that these proteins also play roles in nonapoptotic processes. In addition to its important role in the activation of the intrinsic pathway of apoptosis, other roles for Apaf-1 in cell cycle regulation (47, 48) and spindle formation (Ferraro et al., unpublished data) have been recently described. Furthermore, although the most studied role of the Bcl-2 family of proteins is the modulation of the mitochondrial outer membrane permeabilization, these proteins also localize to the endoplasmic reticulum (ER) (52) . However, the role of ER-localized Bcl-2 proteins is still controversial (53, 54) . Recent evidence indicates that alterations in the ER (Fig. 3C) . The mutual regulation between Bcl-xL and Apaf-1 apoptotic activity has been previously reported (44, 56) , although the proposal of a direct protein -protein interaction is not exempt of controversy (44, (56) (57) (58) (59) and accessory mediator proteins have been described (60, 61) . The pathogenic mechanism of HD is likely to be multifaceted, involving multiple regulatory pathways along with mitochondrial dysfunction and apoptosis induction. The evidence presented here may open new lines of investigation for drug development and future treatments.
Apoptotic proteins play roles in non-apoptotic processes such as cellular differentiation, cell cycle control and mitochondrial morphogenesis (62) (63) (64) . Owing to the importance and unwanted consequences of protein aggregation in cell pathology, the hypothesis that Apaf-1 contributes to the molecular mechanism of such processes merits further study to provide a more in-depth understanding of the mechanisms controlling the cross talk between the cellular pathways involved.
MATERIALS AND METHODS
Cell culture and reagents
HeLa, HEK293, wtMEFs and AkoMEFs cells were cultured in DMEM supplemented with 10% FBS (Invitrogen) at 378C, 5% CO 2 . Where indicated, cells were treated with 10 mM etoposide (Sigma), 50 ng/ml of TNFa (PeproTech), pan-caspase inhibitor Z-Val-Ala-Asp(OMe)-fluoromethylketone (z-VAD; Tocris) and 50 mM minocycline (Sigma). Lipofectamine TM 2000 (Invitrogen) was used according to the manufacturer's instructions to transfect HeLa cells with the plasmids EGFP-HDQ23, EGFP-HDQ74 (49, 50) and PCDNA 3 -Apaf-1 (a gift from Professor Gabriel Nuñez). wtMEFs and AkoMEFs were transfected using the Nucleofector II Amaxa system (LONZA).
Recombinant proteins
Overexpression and purification of His-tagged Apaf 1-541 and pc9 were performed as reported previously (65, 66) . rApaf-1 was obtained using the baculovirus expression system as described previously (39) .
Apoptosome reconstitution assay
This assay was performed by incubating rApaf-1 (100 nM) and minocycline (50 mM) in buffer A (20 mM HEPES, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 0.1 mM PMSF) at 308C for 15 min. Next, 1 mM dATP and 1 mM Cyt c were added and incubated for 40 min. Caspase-9 (100 nM) was added, and activity was monitored by the Ac-LEHD-afc substrate (Enzo Life Sciences, 50 mM) using a Victor 2 spectrofluorimeter (l exc ¼ 390 nm; l em ¼ 510 nm).
Caspase 9 activation assay
Caspase 9 was activated with kosmotropic salts, in particular with Na-citrate as reported previously (37) . Enzyme activity was monitored by adding the Ac-LEHD-afc substrate as described above.
Cell extract assay
Cytosolic extracts from HEK293 were depleted of Apaf-1 as described previously (39, 40) . After incubation of rApaf-1 (100 nM) with minocycline or water (control) in buffer A (described above) for 20 min at 308C, cytosolic extract and dATP were added and the mixture was incubated at 378C for 30 min. Ac-DEVD-afc substrate (Enzo Life Sciences) was used to measure caspase 3 activity, using a Victor 2 spectrofluorimeter.
NMR experiments
All spectra were recorded at 298 K with a Bruker Ultrashield Plus Avance II 600 MHz spectrometer equipped with a 5 mm cryogenically cooled TCI probe. An NMR sample consisted of 1 mM Apaf-1 and 20 or 100 mM minocycline from a 50 mM stock dissolved in water to yield protein:ligand ratios of 1:20 and 1:100 for the waterLOGSY and STD experiments, respectively. The sample buffer was 50 mM phosphate, pH 7.0, with 50 mM NaCl; 8 K points were used for a sweep width of 9600 Hz and a total of 1 and 4 K scans were accumulated for the waterLOGSY and STD experiments, respectively.
Cell-based caspase activation assay
MEFS cell extracts were prepared from 1 × 10 5 cells seeded in six-well plates. After 24 h, cells were treated with minocycline for 1 h, then etoposide or TNFa was added. Cells were harvested after 30 h and cytosolic extracts were obtained as described previously (39) . Total protein (60 mg) was mixed with caspase assay buffer containing 20 mM Ac-DEVD-afc substrate. 
Immunoblotting
Immunofluorescence
Cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 and blocked in 2% gelatin in PBS. Cells were labeled with a primary antibody against Cyt c (SC13561; Santa Cruz) followed by anti-mouse IgG conjugated to FITC (Jackson ImmunoResearch). Images were obtained using a Leica DM 6000 microscope (Leica DC500 camera) with a 20× objective. Two hundred cells were counted and classified according to the localization of Cyt c in mitochondria (tubular morphology) or cytosol (diffuse pattern). For EGFP-HDQ-transfected HeLa cells, wtMEFs and AkoMEFs, cells were fixed the same way, then 500 transfected cells were selected and the number of cells with protein aggregates was counted.
